KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 107 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q1 2021. The put-call ratio across all filers is 1.40 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $3,310,000 | -18.2% | 290,577 | 0.0% | 0.12% | -18.9% |
| Q2 2021 | $4,048,000 | -24.7% | 290,577 | 0.0% | 0.14% | -21.4% |
| Q1 2021 | $5,379,000 | +4.8% | 290,577 | 0.0% | 0.18% | +10.3% |
| Q4 2020 | $5,134,000 | +15.3% | 290,577 | 0.0% | 0.16% | +7.1% |
| Q3 2020 | $4,452,000 | -39.9% | 290,577 | 0.0% | 0.15% | -52.8% |
| Q2 2020 | $7,404,000 | +64.6% | 290,577 | 0.0% | 0.33% | +6.2% |
| Q1 2020 | $4,498,000 | +40.0% | 290,577 | 0.0% | 0.31% | +68.7% |
| Q4 2019 | $3,214,000 | +30.0% | 290,577 | 0.0% | 0.18% | +1.7% |
| Q3 2019 | $2,473,000 | -37.1% | 290,577 | 0.0% | 0.18% | -47.0% |
| Q2 2019 | $3,934,000 | -25.0% | 290,577 | 0.0% | 0.34% | -44.3% |
| Q1 2019 | $5,248,000 | -35.7% | 290,577 | 0.0% | 0.61% | -39.8% |
| Q4 2018 | $8,162,000 | -72.7% | 290,577 | -75.2% | 1.01% | -69.6% |
| Q3 2018 | $29,904,000 | +47.0% | 1,172,700 | 0.0% | 3.32% | +44.0% |
| Q2 2018 | $20,346,000 | – | 1,172,700 | – | 2.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
| Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
| HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
| Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
| AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
| RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
| Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
| Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
| Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |